Gilead Sciences (NASDAQ:GILD) has been given a $95.00 price objective by analysts at Mizuho in a research note issued on Monday, February 5th. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s target price indicates a potential upside of 19.77% from the company’s previous close.

Several other analysts have also recently issued reports on GILD. Berenberg Bank set a $96.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Credit Suisse Group reaffirmed a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a research note on Thursday, December 7th. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. Finally, Argus downgraded Gilead Sciences from a “buy” rating to a “hold” rating and increased their price objective for the company from $73.25 to $73.77 in a research report on Monday, November 13th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and an average target price of $87.04.

Shares of Gilead Sciences (NASDAQ:GILD) opened at $79.32 on Monday. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $89.54. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.55 and a quick ratio of 3.48. The company has a market capitalization of $103,613.26, a price-to-earnings ratio of 22.79, a PEG ratio of -1.77 and a beta of 1.22.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm’s quarterly revenue was down 18.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.70 earnings per share. analysts expect that Gilead Sciences will post 6.41 EPS for the current year.

In other news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.64, for a total value of $1,119,600.00. Following the sale, the executive vice president now directly owns 70,988 shares of the company’s stock, valued at $5,298,544.32. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 30,000 shares of the firm’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $79.00, for a total value of $2,370,000.00. Following the completion of the sale, the executive vice president now directly owns 57,114 shares in the company, valued at $4,512,006. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 358,333 shares of company stock worth $28,066,908. 1.30% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of GILD. Capital International Investors lifted its stake in shares of Gilead Sciences by 86.6% in the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock valued at $908,803,000 after buying an additional 5,205,983 shares during the period. Sanders Capital LLC lifted its stake in shares of Gilead Sciences by 102.9% in the fourth quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock valued at $757,119,000 after buying an additional 5,026,015 shares during the period. Skandinaviska Enskilda Banken AB publ lifted its stake in shares of Gilead Sciences by 230.0% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock valued at $399,233,000 after buying an additional 3,434,450 shares during the period. CI Global Investments Inc. lifted its stake in shares of Gilead Sciences by 5,461.1% in the fourth quarter. CI Global Investments Inc. now owns 3,317,627 shares of the biopharmaceutical company’s stock valued at $237,675,000 after buying an additional 3,257,969 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Gilead Sciences by 12,545.5% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,070,327 shares of the biopharmaceutical company’s stock valued at $219,958,000 after buying an additional 3,046,047 shares during the period. 76.47% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Gilead Sciences (GILD) Given a $95.00 Price Target at Mizuho” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://theolympiareport.com/2018/02/09/gilead-sciences-gild-pt-set-at-83-00-by-mizuho.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.